Table 2

Base-line characteristics of patients evaluated at the end of the run-in period.

Treatment groups


Characteristic

Placebo

Diclofenac

EA

Combined

p-value **


n (M:F)

47 (12:35)

49 (11:38)

48 (10:38)

49 (10:39)

0.93c

Age (yr)*

62.70 (7.22)

62.14 (7.53)

65.10 (3.40)

61.84 (8.95)

0.16a

Body weight (kg)*

60.65 (10.24)

57.65 (10.64)

59.89 (9.74)

59.92 (9.66)

0.49a

Height (cm)*

153.94 (6.45)

151.94 (10.71)

152.19 (5.89)

153.32 (6.73)

0.54a

Duration of OA (yr)*

4.98 (3.32)

3.94 (2.83)

6.09 (4.96)

4.53 (3.86)

0.05a

Localization of OA

0.40c

Right/Left knee

2/3

2/6

1/4

3/5

Both knees

42

41

43

41

Number of paracetamol tablets taken per week*

22.06 (13.75)

18.94 (14.68)

21.40 (14.97)

19.04 (14.87)

0.63a

50 ft-walk time (sec)*

22.04 (4.81)

22.36 (6.00)

24.54 (8.14)

22.77 (5.13)

0.21a

VAS*

63.49 (22.36)

64.79 (23.41)

66.87 (22.34)

57.63 (21.21)

0.21a

WOMAC*

Pain index

10.19 (4.20)

11.02 (4.15)

10.25 (3.86)

10.50 (4.18)

0.75a

Stiffness index

4.51 (1.71)

4.08 (1.95)

4.35 (2.10)

4.27 (1.57)

0.72a

Disability index

37.04 (12.00)

35.65 (12.89)

38.00 (13.18)

37.94 (13.02)

0.79a

Total score

51.75 (15.96)

50.76 (17.98)

52.60 (18.13)

52.71 (17.65)

0.94a

Lequesne's functional index*

13.78 (3.78)

13.85 (3.22)

14.14 (2.98)

13.73 (2.92)

0.93a


*Data represent mean (SD) **Statistic analysis: a = one-way ANOVA, c = chi-square test.

Sangdee et al. BMC Complementary and Alternative Medicine 2002 2:3   doi:10.1186/1472-6882-2-3

Open Data